June 14-16, 2009 - San Diego Marriott Hotel

Supplement- Speaker Bios

Dr. Mark Benedyk, Head, The Pfizer Incubator

Dr. Mark Benedyk is Head of The Pfizer Incubator LLC, a company created by Pfizer to offer scientist-entrepreneurs an opportunity to bring their medical innovations to patients. Prior to joining The Pfizer Incubator, Dr. Benedyk was Vice President of Business Development at Ascenta Therapeutics, a clinical-stage company developing pro-apoptotic small molecule drugs for the treatment of cancer. There he led contract and licensing negotiations for Ascenta, and was part of the executive team that secured $50 million for Ascenta’s Series C financing.

Before coming to Ascenta, Dr. Benedyk was Vice President of Business Development and Director of Optimer Biotechnology, an international biotechnology subsidiary of Optimer Pharmaceuticals, with operations in the U.S., Singapore and Taiwan. At Optimer he led business development activities for Optimer Biotechnology in Singapore, and was part of the executive team that raised $22 million for the Series C&D financing rounds for Optimer prior to its successful IPO in February of 2007.

Previously, Dr. Benedyk has held business development positions at rila bioconsulting, Farmal Biomedicines, Aurora Biosciences (now Vertex Pharmaceuticals), lan Pharmaceuticals, and Argonex Corporation. During his tenure in the pharmaceutical and biotechnology industries, Dr. Benedyk has personally led transactions worth over $300 million and participated in over $500 million worth of product licensing, corporate acquisition and fundraising transactions. Dr. Benedyk received his Ph.D. in Genetics and Developmental Biology from The Rockefeller University, where he was a Lucille P. Markey Graduate Fellow. He received his B.S. in Microbiology and Botany from the University of Michigan.

G. Steven Burrill, CEO, Burrill & Company

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS), BioImagene and NewBridge, and is a member of the Boards of Directors of Catalyst Biosciences, CrossCart, DepoMed (NASDAQ: DEPO), Ikano Therapeutics, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50), and in 2008, he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

Peter Beattie, Former Queensland Premier

The Honourable Peter Beattie is Queensland’s Trade and Investment Commissioner for the Americas. He was Premier (Governor) of the state of Queensland from June 1998 to September 2007, when he retired and handed over to his deputy.

As Premier his key strategy was to turn Queensland into Australia’s Smart State by refocusing the education system, skilling the workforce, encouraging research and development and creating thousands of long-term, new-age jobs in high tech industries such as biotechnology, information technology and aviation.

After working as a lawyer, Mr. Beattie was elected to State Parliament as the Member for Brisbane Central in 1989. He was immediately appointed as the chairman of the reforming Parliamentary Criminal Justice Committee. From July 1995 he served as Minister for Health before becoming Leader of the Opposition in February 1996.

Peter Beattie

Dr. Mark Benedyk

G. Steven Burrill

Kay Chandler, Partner, Cooley Godward

Kay Chandler is a partner in Cooley Godward Kronish’s Business department and an active member of the Firm’s Life Sciences practice group.

Ms. Chandler specializes in representing public and private life sciences companies in a wide range of securities, corporate and commercial matters that are critical to their businesses. She advises clients on all aspects of securities and corporate matters, including private financings, public offerings, mergers and acquisitions, and corporate governance and disclosure issues. She regularly counsels companies on complex commercial transactions, including technology licenses and acquisitions, research and development collaborations, supply, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements, based on her extensive experience in assisting clients to establish and maintain relationships with pharmaceutical, medical device, chemical and agricultural companies in the United States, Europe and Asia. She works closely with her clients to understand each client’s business and strategic objectives and to structure and negotiate transactions to meet those objectives.

Kay Chandler

Nancy T. Chang, Ph.D., Chairman and Sr. Managing Director for Asia at OrbiMed Healthcare Fund Management. Nancy T. Chang, Ph.D. is currently Chairman and Sr. Managing Director for Asia at OrbiMed Healthcare Fund Management. Dr. Chang was Co-Founder of Tanox, a biotech and pharmaceutical company in Houston, and served as Chairman, CEO and President at different times from 1986-2007 . From 1982 to 1986, Dr. Chang served as Director of Research at Centocor, Inc. From 1986 to 1991, she was Associate Professor of Virology at Baylor College of Medicine. Dr. Chang serves on the Boards of Project Hope, Charles River Laboratories and a number of private biotechnology companies. Dr. Chang received a Ph.D. in biological chemistry from Harvard University.

Jonghoon Choi, Executive director, Korea Biotechnology Industry Organization

Dr. Jonghoon Choi, has been working for Korea Biotechnology Industry Organization since early 2008 as an executive director. Before joining Korea BIO he served a director of business development at LG Life Sciences from 2004 for four years. And from 2002 to 2004 he worked for strategic planning and marketing department at Korea Institute of Toxicology. Dr. Choi, received a MS and Ph.D. in the field of toxicology from Miami University and worked as a postdoctoral research fellow at North Carolina State University.

Nancy Chang

Jonghoon Choi

Sang Chul Kim

Hoon Y. Chung

Sang Chul Kim, Director General, KOTRA – Los Angeles

Mr. Sang Chul Kim has been working for KOTRA (Korea Trade-Investment Promotion Agency) since 1983. Since joining KOTRA, he has worked in six different offices of KOTRA. During his early years, he has worked in Kuala Lumpur, Tokyo and Tripoli before becoming a team leader of Asia Pacific team at KOTRA headquarter. He was also the Director General at KOTRA’s Budapest office. He is also the author of ‘25 O’clock, Eastern Europe’. Mr.Kim has been serving the Los Angeles area since 2007 and have been building relationships in the Biotechnology industry including Biocom.

Hoon Y. Chung, Founder and President, MedExGen Inc.

Hoon Y. Chung, M.D., Ph.D. is a founder and president/CEO of MedExGen Inc, a spin-off life sciences company at Hanyang University, Seoul, Korea. After his graduation of Medical school he was working as a clinician in KEPCO hospital, Seoul, Korea for 3 years. He was a research fellow in Sloan-Kettering Institute in New York for 2 years. He has served as a board of directors of Korean Microbiology Association, and Korean Society of Immunology for 15 years. And he also served as a chief executive of Korean Society of Immunology for 4 years. Prior to founding MedExGen Inc, Hoon has been a Professor of Medical Microbiology and Immunology in Hanyang University for 23 years. During this period of time he published more than 50 papers in the fields of Medical Microbiology and Immunology and has also obtained more than 25 patents through out the world in the field of therapeutic protein innovations.

Peter J. Claude, Advisory Partner, PricewaterhouseCoopers

Peter Claude is a Partner in the San Francisco, CA office of PricewaterhouseCoopers, where he leads our practice serving West Coast pharmaceutical and life science advisory clients. Peter brings an in-depth knowledge of the pharmaceutical and life sciences industry to his extensive process and controls background as well as an international perspective from a four-year tour of duty in Switzerland. Peter’s clients have included a broad range of large and small domestic and multinational pharmaceutical, biotechnology and medical device manufacturers as well as pharmacy benefit managers. His engagements have covered corporate, commercial and R&D compliance issues, channel strategy and commercial contracting and performance improvement, pharmacy benefit manager and wholesaler relationships, government price reporting, and strategic alliances.

Peter was the principal author of “Recapturing the Vision”, PwC’s groundbreaking study on improving the Pharmaceutical Industry’s reputation, and of two published studies on compliance issues in the Medical Device Industry. Peter has spoken at a number of pharmaceutical and medical device industry events on industry and compliance and related process improvement topics.

Peter J. Claude

John D. Diekman , Founder and Managing Partner, 5AM Ventures

John D. Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Dr. Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Dr. Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director. Dr. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. He is also Vice-Chairman of Singapore’s Life Science Fund, Bio*One Capital. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Dr. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman is based in the Menlo Park, CA office.John Diekman

Lisa Conte, Chief Executive Officer, Founder, Napo Pharmaceuticals

Lisa has been a pioneer in the biotech/emerging pharmaceutical industry for 20 years. She is founder and CEO of Napo Pharmaceuticals, which brings proprietary products to the global marketplace through local partnerships. Napo embraces the “triple bottom line” goals of enhancing financial return by addressing global health needs in its development strategy and environmental sustainability in sourcing its lead product, which is harvested from rain forest areas. Prior to founding Napo, she founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company, in 1989. As CEO, she has raised >$250 million (including leading two IPOs). 1987 to 1989 Ms. Conte was a Vice President at Technology Funding, Inc., a venture capital firm. From 1985 to 1987 she conducted risk and strategy audits for start-up companies at Strategic Decisions Group. Lisa received her AB in Biochemistry from Dartmouth College, her MS in Physiology/Pharmacology from the University of California at San Diego and her MBA from the Amos Tuck School, Dartmouth College. She is the recipient of several entrepreneurship awards, including the 1994 E&Y Entrepreneur of the Year Award, has sat on several industry and academic boards, and is a nominee for the 2009 BIO Humanitarian Award.

Lisa Conte

Rachel Gong, Healthcare Investment, Morningside Ventures

Dr. Gong joined Morningside in 2004, and has been focused on the firm’s healthcare investments. She represents Morningside on the board of several private companies. Dr. Gong has both operating and investment experiences in the biotechnology industry in China and the United States. In the U.S., Dr. Gong has held positions in biotech management (QIAGEN), public accounting (PricewaterhouseCoopers), and investment banking (RBC Capital Markets). Earlier in her career, she was a researcher at the Chinese Academy of Medical Sciences in Beijing. Dr. Gong received her Ph.D. in Biochemistry and Molecular Biology from the University of South Florida, her M.B.A. from Cornell University, and her B. S. in Plant Physiology and Biochemistry from Beijing University.

Rachel Gong

Anand GovindaluriI, Executive Director & Chief Investment Officer for Fortunis Ventures Private Limited, India

Anand Govindaluri is the Managing Director & CEO of GO-VIN Holdings, Singapore and as well as GO-VIN Investments & Advisory Services, India. GO-VIN Holdings is an investment holding company with a focus on direct investments in healthcare in Asia. In particularly, we specialize in the Indian markets.

Anand is healthcare investor by profession with several years of experience in investing in biotechnology, pharmaceutical and healthcare companies globally. He focuses across the value-chain of healthcare investments - from deal sourcing, to conducting on-site due-diligence, serving on the boards of companies for strategic development and planning exit strategies.

Anand has a Masters in Business Administration from the California State University, Hayward, USA; Masters in Biological Sciences from the National University of Singapore and Masters in Molecular Biology and Biotechnology from G B Pant University, India.

Anand Govindaluri

Juan M.E. Harrison, Vice President, TRI

Mr. Harrison joined TRI as Vice President in January 2008. He brings more than 21 years of biopharmaceutical R&D, product licensing, business development and strategy experience. Most recently, Mr. Harrison was a partner with ProPharma Partners International, where he specialized in developing and implementing business and licensing strategy for emerging and established biopharmaceutical companies. Prior to this, he held senior business development positions at XenoPort Inc., PowderJect Inc., Connetics Corporation and Alza Corporation. In addition, Mr. Harrison held product development management and research positions at Alza, where he began his career in 1985. Mr. Harrison received his Bachelor of Sciences in Combined Sciences from Santa Clara University in California, USA.

Juan Harrison

Andrew de Guttadauro, Vice President Corporate Development, Vical Incorporated

Andrew R. de Guttadauro joined Vical as Vice President, Corporate Development in August 2007. Prior to joining Vical, Mr. de Guttadauro was Senior Director of Strategy at Biogen Idec since February 2007, following a two-year assignment overseeing the commercial development of that company’s Zevalin, the first radioimmunotherapy product approved for use in the United States. Before joining Biogen Idec, he spent the prior year at MedImmune, where he directed marketing efforts for the FluMist inhaled influenza vaccine. Mr. de Guttadauro served in various marketing positions of increasing responsibility at Amgen Inc. over a six-year period, with direct involvement in the marketing of Enbrel, Kineret, Aranesp, and Epogen products. He spent the first seven years of his career at Tap Pharmaceuticals, where he served in a series of sales and marketing positions, including contributions to the success of Prevacid and Lupron. Mr. de Guttadauro earned a bachelor of science degree in engineering from the United States Military Academy at West Point, followed by a three-year tour of duty as a Captain in the U.S. Army.

Lisa A. Haile

Lisa A. Haile concentrates on patent protection with special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening, and bioinformatics. Particular experience with patentability, non-infringement, and validity opinions, licensing strategies, FDA counseling, due diligence work in connection with venture capital, private, and public financing, mergers and acquisitions in the life sciences industry, and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Haile is a member of DLA Piper’s firmwide Policy Committee.

Partner, Richard J. Hammel, International Business Consultants, Inc.

RJH, IBC is a pharmaceutical/biotechnology consulting firm which provides a broad range of business, financial and product development services. The partnership was founded by a team of pharmaceutical industry executives with the goal of providing technology assessment, strategic planning, financial planning, product development and business development/licensing services to the pharmaceutical/biopharmaceutical industry. RJH, IBC has offices in the United States, and affiliates in Europe and Japan. Principals of the partnership have comprehensive industry experience which extends across financing, pre-clinical and clinical development, strategic and regulatory planning, product licensing and sales and marketing. Clients include biotechnology companies, US. European and Japanese pharmaceutical companies.

Andrew de Guttadauro

Lisa A. Haile

Richard Hammel

Charles Hsu, Ph.D. Venture Partner, Bay City Capital, LLC

Dr. Hsu has over 25 years of life science industry experience, including 19 years as an entrepreneur and venture capitalist, focused on life science and healthcare. He was a General Partner of the Walden Group and its affiliate Walden International from 1996 through 2003. Prior to joining Walden, he co-managed life science investments at Advent International, a global private equity firm based in Boston. He has co-founded or invested in over 25 companies, and/or has served as a Director of, companies such as Axys Pharmaceuticals, KOSAN, Lexicon Genetics, Telik, Biomatrix, RPI (later Sirna) and Aviron, Inc., all of which went public on NASDAQ.

Dr. Hsu has been investing internationally throughout his career, and has been involved with a number of companies outside the U.S., in roles such as founder, investor, director or advisor. Some of these companies include D-Pharm, Asia Renal Care, Mindray, Eureka, Progentech, LEAD Therapeutics and Wuxi Pharmatech. He is a frequently invited speaker and published author on various topics related to life sciences investing. He holds an AB in Biochemistry from Harvard and his PhD and MBA from Stanford.

Charles Hsu

Chris Holloway, Group Director of Regulatory Affairs, ERA Consulting

Dr. Chris Holloway is Group Director of Regulatory Affairs at ERA Consulting, with overall responsibility for the company’s operations. He has worked in regulatory affairs, specializing in biotech products and other biologics, for more than 20 years and has worked on over 350 different products.

Haroon Hashmi, Director, Drug Development - Asia Pacific

Haroon Hashmi is Biogen Idec’s Director of Drug Development for the Asia-Pacific region. In this position, he assesses the market potential of Biogen Idec’s products in Aisa-Pacific. He prioritizes the development pipeline, and oversees the implementation of development strategies in this region. Mr. Hashmi has a combined 12 years of biotechnology experience in the areas of analytical development, regulatory (U.S., EU, Canada and Japan) and program management. His previous positions at Biogen Idec include Director of Regulatory Affairs, where he was responsible for three early stage and two late stage programs, and Program Manager within the Program and Alliance Management Department, where he drove the drug development program in Japan.

Prior to joining Biogen Idec in 2002, he worked for Biomira Inc., a biotech company focusing on cancer vaccines, in Edmonton, Canada. Haroon is working on his PhD in Public Health - Epidemiology and currently holds and MSc in Experimental Medicine (Oncology) from the University of Alberta, Edmonton, Canada and an MSc in Microbiology from the University of Karachi, Pakistan.

Chris Holloway

Haroon Hashmi

Steven Hutchins, Vice President Business Development WuXi AppTec

Mr. Hutchins received a BS degree in chemistry from the University of New Hampshire and joined Merck’s medicinal chemistry department 1990. Steven worked on cardiovascular and inflammation targets prior to becoming a founding member of Merck’s central combinatorial chemistry group. He began his involvement in outsourcing of chemistry services with Merck in 1995 and in later years expanded his sourcing role from chemistry to include all of the services (medicinal & process chemistry, formulation, biology, pharmacology, drug metabolism and bioprocess R&D) required for both Basic Research and PreClinical Development. Throughout his 12 year outsourcing career at Merck Steven developed relationships with companies throughout the world including North America, Europe, China & India.

Steven currently holds the role of Vice President of Business Development at WuXi AppTec where he is responsible for leading the company’s global business development and reinforcing WuXi’s brand value and market leadership.

Steven Hutchins

Dinesh Jain, Founder and CEO, Aagami, Inc.

Dinesh is the Founder CEO of Aagami, Inc. providing services to Global Life Sciences companies covering all sectors like Biotech, Pharma, Drug Delivery technologies, Nutraceuticals and Medical Devices. These Strategic Consulting and Drug development services encompass Global M&A, In- and Out-Licensing, Clinical Trials, Pharmacology studies, PreClinical Toxicity studies, custom synthesis of small and large molecules, etc. Aagami clients range from a two people virtual biotech company to 20,000 people large Pharma/chemical companies. Some of them are Dow, Solvay, the pioneer of biotech, Depomed, Aegis Therapeutics, BioQuant, Unitech Pharma, Epicept Corporation, InterHealth etc.

Before switching to Life Sciences, Dinesh led several companies in Technology industry across the Globe in Top executive positions like CEO, VP and Representative Director etc. He formed JV, Alliances and developed as customers some of the top notch companies of the world like Nomura Research, IBM, Unisys, NEC, Toshiba, Mitsubishi, Daewoo, Computer Associates, ONGC and AMP. During that period Dinesh has lived and worked in US, Japan, India and Spain and have managed businesses in US, UK, Japan, India, Israel, Australia, Singapore, South Korea, Ireland, and Sri Lanka.

Dinesh Jain

Kyeong Hoon Jeong

Kyeong-Hoon Jeong, CSO, Mazence

Kyeong-Hoon Jeong, PhD is CSO and vice chair in Mazence Inc. He started his career in LG Life Sciences Ltd, where he served as a scientific researcher until 1993 and was involved in developing biological and pharmaceutical drugs.Dr. Jeong received his PhD in biology from Boston University in 1998, and completed his post-doctoral research fellow training at Children’s Hospital Boston and Brigham and Women’s Hospital, Harvard Medical School, under mentorships by Joseph A Majzoub, MD, William W Chin, MD, and Ursula B Kaiser, MD. He served as an instructor in medicine at Brigham and Women’s Hospital, Harvard Medical School until his returning back to Korea in 2006.

Anula Jayasuriya, Managing Director, Evolvence India Life Science Fund

Anula Jayasuriya , MD, PhD, MBA ‘93 Founding Partner, LifeScience-India Fund Anula Jayasuriya is a founding partner of Life-Science India, an affiliate fund of Draper Fisher Jurvetson, which invests in US companies that are leveraged by performing core strategic functions in India. She was previously a partner with Skyline Ventures, and prior to that with the German-US venture capital firm TVM.

Anula Jayasuriya

Kewen Jin

Kewen Jin, General Manager, Charles River Laboratories Kewen Jin is currently General Manager of Charles River Laboratories (CRL) China preclinical service company. He was founder/CEO of BioExplorer, a preclinical CRO which formed a JV with CRL in 2007.

Kewen has co-founded and served as key executive (CEO, CBO, and founding partner) for three other companies in the R&D outsourcing, drug discovery, and consulting. He served as advisor to several MNC pharma and healthcare companies, major consulting and investment firms. Previously, he was a marketing and international operation executive with Wyeth, first five years in the U.S. , then two years in Beijing.

He is a Senior Advisor to Shanghai Pudong Government. He was granted the 2005 Magnolia Award, which the Shanghai government grants to individuals making major contribution to the development of Shanghai. He is a member of the Board of Directors for Bayhelix and Sino American Pharmaceutical Association (SAPA), two leading Chinese life science professional organizations.

He was trained in medicine (Shanghai Jiaotong University School of Medicine), biology (Rockefeller), finance (Columbia).

Wendy Johnson, Venture Partner, ProQuest Investments

Ms. Johnson joined ProQuest as a Venture Partner in 2005 and brings broad experience in licensing, strategy, and corporate development. She has successfully licensed multiple value-generating therapeutic products, negotiated acquisitions, and established several international strategic alliances. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix Inc., where she led the effort to license their lead cancer therapeutic; the company was successfully sold to Cephalon in June 2005. Ms. Johnson has additional experience with device, diagnostic and drug discovery and development and regulatory affairs. She held senior business and corporate development positions at Women First, Prizm Pharmaceuticals (currently Selective Genetics Inc.), Cytel Corp., Symbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant Director with the Center for Devices and Radiological Health at the Food and Drug Administration. Currently, Ms. Johnson serves as the President and CEO of Aires Pharmaceuticals, a ProQuest portfolio company. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.

Wendy Johnson

Dr. Frank Kung, Managing Partner

Dr. Kung is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.

Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

Dr. Frank Kung

Ravi Kiron, Managing Director, Adjuvant Global Advisors, LLC

Dr. Ravi Kiron has over 20 years of experience in the pharmaceutical and healthcare industry and is currently Managing Director at Adjuvant Global Advisors, LLC. Dr. Kiron is well versed in all aspects of drug discovery and delivery; pre-clinical and early clinical drug development; bioinformatics and database management; M&A, investment due-diligence, and alliance management.

Prior to Adjuvant, Dr. Kiron was the Chief Operating Officer at LifeTech Innovations (LTI), a Business Development and Strategic Advisory consulting firm. Before LTI, he was at Johnson & Johnson/ALZA Corporation, responsible for drug delivery technology & research strategy planning, in- and out-licensing, M&A and intellectual property management. Earlier to J&J, Dr. Kiron spent 13 years at Pfizer Global R&D in the departments of Strategic Alliances, Project Management and Cardiovascular Drug Discovery. He holds a BSc in Chemistry and an MSc in Microbiology through colleges in Goa from Bombay University, India. He also earned a PhD in Biochemistry from the Indian Institute of Science in Bangalore, India and an MBA from Rensselaer in Hartford, Connecticut.

Ravi Kiron

Stephen Lam, Senior Manager, Hong Kong Science & Technology Park

Stephen Lam, Ph.D., MBA joined the Hong Kong Science and Technology Parks Corporation (HKSTP) in November 2006 and is currently a Senior Manager, with the responsibility to develop the Life Sciences and Biotechnology cluster. He brings to the organization over two decades of research, management, and business development experience in the biotechnology industry. Prior to joining HKSTP, Dr. Lam served roles of increasing impact at several multi-national corporations including CIBA-Geigy, Novartis, Syngenta, and Pioneer (a DuPont Company). He also served as founder and Chief Operating Officer of Aryzun Pharmaceuticals, an early-stage drug development company focused on infectious diseases and oncology. He earned his B.A. at the University of Oregon, his MBA at Duke University, and his Ph.D. at the University of Utah. Dr. Lam is an inventor on 16 issued US patents and authored over two dozen scientific publications.

Stephen Lam

Vivian Lee

Vivian Lee, Partner, Aqua Partners

Vivian Lee has 25 years experience in life science advisory, investment and portfolio management. Served as Venture Partner of Global Biomedical Partners (GBP), managing $100 million BIOMEDICINE fund. Former member of Board of Directors of Innodia Inc and observer on board of Syntonix Pharmaceuticals. Has advised hundreds of companies, investment firms, universities and government agencies worldwide, frequent speaker at biotechnology investment conferences in US, Europe and Asia, served as a reviewer to the US Congressional Office of Technology Assessment in its first report on commercial biotechnology in 1983. Previously associated with Adler & Co., Euclid Partners and the corporate venture arm of WR Grace & Co. A.B., Biochemistry from Harvard University, conducted research in tumor immunology at Dana Farber Cancer Center and Yale University.

James Li, Kleiner Perkins Caufield & Byers

Dr. James Li joined Kleiner Perkins Caufield & Byers in October 2006.Prior to joining KPCB, James spent over 15 years of outstanding service with Merck Co. where he held positions of increasing responsibility in basic research, clinical research, regulatory affairs, new product development/access and franchise management, all with an Asia Pacific focus.

James has been a known expert in the Asia Pacific pharmaceutical industry. He has published a number of papers on the region’s clinical, regulatory access and marketing issues and has been a regular speaker and guest consultant for a number of government regulatory agencies, academic institutes and industry associations.

From 1996 to 2000, James was the Medical Director of Merck’s China Operations, where he successfully developed a first class professional medical team, conducted early phase clinical studies, and developed strong relationships with government regulatory agencies, key opinion leaders, and top research institutes.

James received his Medical Degree from Shanghai Medical University, completing an internship in Internal Medicine and a rotation in Oncology, followed by a Master of Science degree in Microbiology from the University of Montana.

James Li

Christopher C. LeMasters, Co-Founder & Chief Business Officer, Tragara Pharmaceuticals

Mr. LeMasters joins Tragara after serving as Chief Business Officer and co-founder of Cabrellis Pharmaceuticals. At Tragara, he completed the negotiation with Daiichi-Sankyo for the company’s founding license to CS-706 (TG01, apricoxib). He also negotiated the world-wide license to SB1317 (TG02) from S*BIO Pte Ltd of Singapore. At Tragara, Mr. LeMasters oversees the administrative and operational functions of the company, including finance and accounting, intellectual property, and corporate development. While at Cabrellis, Mr. LeMasters was responsible for negotiating the $104 million acquisition by Pharmion Corporation. Previously, he served as Vice President, Business Development of Conforma Therapeutics where he was responsible for the in-licensing of Amrubicin from Dainippon Sumitomo and for negotiating the $250 million acquisition by Biogen Idec. Mr. LeMasters earlier worked for six years in Corporate Business Development at Eli Lilly and Company in Indianapolis. In that role, he was responsible for the successful negotiation of numerous partnerships and licenses across diverse therapeutic areas. Mr. LeMasters has a B.A. in Finance from Indiana University and an M.B.A. with honors from the University of Chicago and is a Co-Founder and Board Member of Aarden Pharmaceuticals.

Chris LeMasters

George G. Montgomery, Managing Director, Montgomery, Marshall Healthcare Partners, LLC

George G. Montgomery is a co-founder and Managing Director at Montgomery, Marshall Healthcare Partners, LLC. Over the past 25 years in investment banking, George has had extensive experience in all types of public and private financings and M&A advisory work, including sell-side, buy-side, divestitures and partnerships. Over the past 20 years, George has worked across all sectors in the healthcare industry and has focused on biotechnology, pharma and medical devices. He has been involved in over $20 billion in completed M&A transactions, over $700mm in private equity placements for biotech and device companies and several billion in public equity and debt offerings.

Prior to founding MMHCP, George joined Montgomery & Co., LLC in 2003 and led the firm’s healthcare effort from inception and opened its San Francisco office. While there, George served on the Board and the Executive Committee of the firm and helped grow the firm from approximately $5mm to $55mm in annual revenues. At Montgomery & Co, George’s healthcare team raised approximately $500 million in private equity, completed over $600mm of public equity offerings and completed approximately $1.5 billion of M&A. While at Montgomery & Co, George and his team built extensive relationships with leading Japanese pharmaceutical companies and completed over $1 billion in cross-border financings.

George received his BA from Yale College and his MBA from the Wharton School at the University of Pennsylvania. George and his wife and seven children live in the Bay Area. He has coached AYSO soccer for 16 years and has been active in fundraising for the American Heart Association. He also currently serves on the Cal Parents’s Board at UC-Berkeley.

George Montgomery

Myung Hwan Park, Executive Director, GyeongGi Bio-Center

Dr. Myung Hwan Park, has been working for GyeongGi Bio-Center(GGBC) since 2007 as an executive director. He graduated Seoul National University majoring in Pharmaceutical Manufacturing(B.S.) and also studied in graduate school of Same Univ. in Pharmacognosym(M.S.) and Natural Products Chemistry(Ph.D). Dr. Park worked as a postdoctoral research fellow at Dept of Chemistry, Columbia University from 1987 to 1989. Before joining GGBC, he served a CEO & President at Ambo Institute from 1999 for seven years. And from 1992 to 1999 he worked as Director at research and development center, Daewoong Pharmaceutical Company, Ltd. Dr. Choi, received a MS and Ph.D. in the field of toxicology from Miami University and.

Myung Hwan Park

Colleen Coyne Nelson, Professor and Chair, Prostate Cancer Research, Institute of Health and Biomedical Innovation, Queensland University of Technology

Professor Colleen Nelson is the founding Executive Director of the Australian Prostate Cancer Research Centre-Queensland and Chair of Prostate Cancer Research at Queensland University of Technology. The Centre, based at the Princess Alexandra Hospital, spans the spectrum of discovery of new therapeutic targets and their preclinical and clinical development. Prof Nelson is also Director of the Australian-Canadian Prostate Cancer Research Alliance, an initiative developed to coordinate national and international network interactions of >200 prostate cancer scientists and clinicians in Australia and Canada, facilitating access to state-of-the-art infrastructure and clinical trials to assist in the translation of a wide range of discoveries in both countries. Since arriving in Australia in 2007, Prof Nelson has been awarded >$15 million in research grants. Prior to her appointment in Australia, she was a founding scientist of The Prostate Centre in Vancouver, a National Centre of Excellence in Research and Commercialization. Over the past decade she has worked in close collaboration with Director of the Vancouver Centre, Dr Martin Gleave. During that period, she has been awarded research grants totalling >$100 million (Canadian) from most of the key biomedical funding agencies and industry in North America for peer-reviewed operating funds and establishment of state-of-art research facilities.

Colleen Coyne Nelson

Sri(dhar) Mosur, CEO and President, Global Discovery and Development at Jubilant Organosys Ltd

Sri(dhar) Mosur is the CEO and President, Global Discovery and Development at Jubilant Organosys Ltd, a leading Indian pharmaceutical vertical focused on providing drug discovery and development, manufacturing and health care solutions to the global pharmaceutical and healthcare industry.

A chemical Engineer by training, Sri is involved in developing and directing R&D and healthcare alliances between the mature and emerging markets. Over the last decade Sri has actively directed and participated in developing successful and pioneering alliances across functional outsourcing, partnered R&D, joint ventures between academia, the investment community and the global pharmaceutical industry in the areas of pharmaceutical research, development and global healthcare. Sri has been involved in several unique and globally leveraged risk bearing investment and networked partnering models. Having worked with the major pharmaceutical, biotech, venture funding and CRO industry over the last two decades, Sri brings a very good perspective of the needs, capabilities and the potential synergies between the mature and emerging markets.

Sri Mosur

Michael Newman, Executive Vice President, Oncology, HUYA Bioscience International

Dr. Newman leads the development of HBI-8000 and all of HUYA’s other cancer-targeting compounds. Prior to joining HUYA, Dr. Newman was most recently Chief Scientific Officer at Dihedron Corp. Prior to Dihedron, he served as the Vice President of Biology for Ontogen Corp., where he managed drug discovery programs in oncology and metabolic diseases. Before joining Ontogen, Dr. Newman was Executive Director of Oncology and Head of Cancer Biology in the US for Novartis Pharmaceuticals. Dr. Newman holds a PhD in Cell and Development Biology from Harvard Medical School and completed Post-Doctoral training at Cornell University. He holds a bachelor’s degree in Biology from the University of California, San Diego (UCSD).

Michael Newman

Leslie Pryce, President, New Business Horizons

Leslie has 16 years experience of working as a development partner for companies seeking successful Alliances with the Asia Pacific region. His company has completed a number of significant licensing deals. Pryce was Founder and EVP Glaxo Korea and Director of Business Development for Colgate Palmolive Far East.

Leslie is the Japan based partner of two major USA venture fund organizations and the major global OTC consulting organisation Nicholas Hall and company. Leslie is a Board member of the Japan Pharma Licensing Association and has been invited to join the LES Japan. (Subject to Board approval)

Leslie Pryce

Mario Pennisi

Mario Pennisi – Chief Executive Officer

Mario has extensive experience managing laboratory medicine services and strategic marketing. In the mid 1990s in affiliation with US and German based organisations he established the first Queensland based ‘central laboratory’ in order to service international clinical trials in the Asia-Pacific region. He was also a founding member of the first Queensland based contract research organisation (CRO). Later, as National Business Development Manager for an Australian multinational pharmaceutical/diagnostics company, collaborating with numerous international sponsors and service providers to achieve significant clinical trials growth in Australia . Mario is an active member of the Queensland Life Sciences Industry – and is helping establish a strong network of alliances across the Asia-Pacific region.

Mario has been CEO of QCTN for over four years and during which time the organisation has grown to have a membership base of over 70 members and is now being recognised as Australia ’s peak clinical trials industry association.

Kourosh Parivar, Head Clinical Pharmacology, Oncology Business Unit, Pfizer Inc, La Jolla

Kourosh received his M.Pharm. in 1989 from Uppsala University, Sweden, after which he completed his post-graduate training in pharmacokinetics at the University of California, San Francisco (UCSF). In 1991, after returning to Sweden, he accepted a position as Clinical Research Scientist at the department of Clinical Pharmacology at Astra Arcus AB in Sodertalje, Sweden, and worked with different compounds in the CNS therapeutic area. In 1993, Kourosh joined Pharmacia AB in Stockholm, Sweden, as Clinical Research Manager and was in charge of the Clinical Pharmacology development of their intravenous anesthetic drug. In 1996, Kourosh accepted a position as Clinical Pharmacology Program Leader at Pharmacia & Upjohn AB and worked with development of several compounds for treatment of diabetes and erectile dysfunction. In 1999, Kourosh was appointed as the head of Clinical Pharmacology at Pharmacia & Upjohn AB in Stockholm, Sweden. In 2000, Kourosh moved to Singapore on behalf of Pharmacia to set up a Phase I Research clinic which was completed in late 2001 after which he was appointed as the head of Clinical Pharmacology at Pharmacia’s R&D facility in Chicago, USA, working with Pharmacia’s anti-inflammatory portfolio. In 2003 Kourosh joined Pfizer as head of Clinical Pharmacology covering antiviral, oncology, diabetes and ophthalmology therapeutic areas. He is currently the head of Clinical Pharmacology for the Oncology Business Unit at Pfizer. His areas of interest are quantitative drug development and drug development in Asia.

Kourosh Parivar

Mark E. Saad, Chief Financial Officer, Cytori Therapeutics

Mark E. Saad joined Cytori Therapeutics as Chief Financial Officer in June 2004. Previously, Mr. Saad served as Chief Operating Officer of UBS, Healthcare Investment Banking, New York, where he was responsible for global investment banking operations. Upon joining UBS, Mr. Saad served as Executive Director covering life sciences sectors - biotechnology and medical devices. Prior to joining UBS, Mr. Saad held the position of Financial Analyst/Associate with Salomon, Smith Barney, Healthcare Investment Banking, New York, where he managed public and private transactions. Mr. Saad holds a B.A. from Villanova University, Philadelphia, PA.

Mark Saad

J. George Sarmiento, PhD, Sr. Director

George Sarmiento, has recently rejoined the Business Development Group at Astellas US following a two year period at NextWave Pharmaceuticals where he was responsible for licensing activities at this specialty pharmaceutical company. While at Astellas (Fujisawa), George had been involved in multiple therapeutic area licensing deals, including the Lexiscan (CV Therapeutics) and Vernakalant (Cardiome) products. George has a broad licensing and deal making experience which includes Rx products, contract manufacturing, and co-promotion deals.

George received his Ph. D. from the University of Illinois, School of Medicine (1980) and held a faculty position at the University of Connecticut, School of Medicine (1980-1985). His research was supported by grants from AHA and an NIH Program Project. George joined Bristol Myers Squibb as a Sr. Research Scientist in 1985 and conducted drug discovery research in CV, CNS, GI and Oncology therapeutic areas. In 1990 George joined the newly formed Fujisawa Pharmaceutical Company US, the first Japanese Pharma to have independent US operations.

Sylvie Sakata, Senior Director, Head of External Research Solutions La Jolla Site, Pfizer, Inc.

Sylvie received her Bachelor of Science with Honors at the University of California Irvine in 1993. She continued her studies organic chemistry and natural product synthesis with Professor Larry Overman, and obtained her PhD at UCI in the fall of 1998. She started her career in industry at Agouron Pharmaceutical in the Chemical Research and Development as a research scientist and had the opportunity to lead projects within Development. Over a three year period, while in CRD, she worked on the development of the Rhino Virus (common cold) and HIV NNRTI programs. In 2001, she redirected her career to move to Medicinal Chemistry as a Senior Principal Scientist where she has had the opportunity to continue to work in many Antiviral programs at Warner Lambert now Pfizer. During the same period, she led the entire chemistry sourcing strategy for Pfizer La Jolla. She held the Associate Director of Chemistry Sourcing leading all chemistry services for both Pfizer La Jolla (2006-2008) and in 2006-2007 Pfizer Nagoya Research Site. In mid 2008 to present, she holds the position of a Senior Director to lead the External Research Solutions for Pfizer La Jolla in charge of Chemistry, Biology, and DMPK services in the pre-clinical sourcing. She has experienced in working with Asia/EU/North America sourcing partners, API and Analytical services and integrated sourcing programs.

Sylvie Sakata

Zhu Shen

Zhu Shen

Dr. Zhu Shen is an award-winning business leader, author, speaker, media personality, and thought leader in cross-Pacific life science business. She is the CEO of BioForesight, a life science strategic consulting company providing media/public relations, licensing, partnering, investment advisory, CRO/outsourcing strategy, cross-cultural communications/negotiation training to clients globally. Dr. Shen is a frequent speaker and chair of life science business conferences and has been featured on CBS Evening News with Katie Couric, Business Week, Fox News, Los Angeles Times, China Economic Review, Pharmaceutical Executive, Ernst & Young Pharmaceutical Report, San Diego Union Tribune, San Diego Business Journal, and ASIA Media.

Dr. Shen sits on the Editorial Advisory Board of PharmAsia News, the Board of Directors of Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), BIOCOM’s CalAsia Programming Committee, the Athena San Diego Bioscience Committee. Website: www.bioforesight.biz

Masood Tayebi, Executive Chairman, Bioduro LLC

Dr. Tayebi’s ability to build and grow a global multi-billion dollar outsourcing services business is incontrovertible. He brings the wealth of experience and critical insights into the service sector, gained through his success in the telecom industry, and in founding BioDuro, Masood applies the lessons learned to advancing the drugdevelopment industry.

Dr. Tayebi has been involved in founding, financing, and managing numerous companies. Most recently, hefounded, built, and managed WFI, the leading global services firm to the wireless industry. WFI currentlyemploys 2,700, has operations in over 60 countries. In 2000, at the peak of telecom hype, WFI had a marketcapitalization of over $7 billion. Dr. Tayebi is also a partner in Bridgewest, a San Diego Based investment firm that is active in venture capital and real estate investment. BridgeWest has invested in 12 start-up companies including LogicTree and QThink. Dr. Tayebi is a direct investor with sizable holdings in 9 venture firms including Oak Investment Partners and Credit Suisse’s venture fund. Prior to co-founding WFI, Dr. Tayebi enjoyed a successful engineering career with several well known multinational corporations including British Telecom and LCC International. Dr. Tayebi received his Ph.D. in mobile radio propagation from the University of Liverpool, his M.S. in electronics engineering from the University of Southampton.

Masood Tayebi

Ming-Wei Wang, M.D., Ph.D., Director, the National Center for Drug Screening

Following medical practices in Shanghai, Dr. Wang obtained his Ph.D. from University of Cambridge in 1989. He worked for a couple of US-based biotechnology companies a year later and served as a consultant to Merck and UNDP relative to China-related projects in the mid-90’s. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang was appointed to the faculty at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and Director of the National Center for Drug Screening in 2003. He was named by the Shanghai Pudong New District Government as a senior business advisor in 2004.

Ming-Wei Wang

Peter G. Ulrich, Co-Founder, President & CEO, TargeGen

Peter G. Ulrich, has served as an executive in the health care and biotechnology industry for over 30 years, including 8 years at Baxter HealthCare where he held domestic and international marketing management positions. He has over 16 years experience in CEO or senior management capacities in the biotechnology industry with companies including NeuroVir Therapeutics, La Jolla Pharmaceutical Co. and TargeGen.

In conjunction with co-founding TargeGen Inc., Mr. Ulrich served as the first Entrepreneur in Residence for Forward Ventures and assumed the role of president & CEO of TargeGen, Inc. in March, 2002. TargeGen has attracted more than $110M in venture funding and is working on the development of four internally discovered drug candidates. TargeGen was named one of the top 100 venture backed companies in North America by Venture Reporter Magazine. TargeGen’s TG100-115 compound received the UCSD Connect “Most Innovative Product of the Year Award” in 2004. Mr Ulrich was the recipient of the 2006 Ernst & Young “Entrepreneur of the Year Award” in the emerging company category. Mr. Ulrich received his B.A. from the University of Texas (Austin) and an M.S. in International Business Administration from the University of Dallas.

Peter G. Ulrich

John E. Wehrli, Partner, Latham & Watkins

John E. Wehrli is a partner in San Diego office of the international law firm of Latham & Watkins. Mr. Wehrli’s practice focuses exclusively on the representation of life science companies in the biotechnology, pharmaceutical and medical device industries, with particular focus on structuring and negotiating complex “bet-the-company” intellectual property collaboration, corporate partnering, joint venture, spin-out, co-marketing, co-promotion, and strategic alliance transactions with a heavy emphasis on Asian and European cross-border transactions. He has completed over 200 life science intellectual property transactions, including 63 multi million dollar corporate partnering and collaboration agreements, 19 of which were each valued over $100 million and totaled over $8.6 billion. Mr. Wehrli has represented over 170 life science companies in a variety of areas in addition to intellectual property transactions, including patent prosecution, patent litigation, food and drug law, corporate securities, public and private financings, and mergers and acquisitions. Mr. Wehrli has over 24 years of extensive life sciences industry experience at virtually all operational levels ranging from private practice to in-house for the U.S. Government, start-up biotechnology companies, and major multinational pharmaceutical companies and roles ranging from research chemist to company founder to senior business and legal executive of public companies. He has been working in biotechnology intellectual property licensing and patent law since 1995.

John Wehrli

Lisa Walters, Managing Director, Roth Capital Partners

Lisa Walters-Hoffert initially joined ROTH Capital Partners in 1997 and serves as Managing Director in ROTH’s San Diego office. Her principal areas of focus are life sciences and medical technology. Since 1986 Ms. Walters has held numerous positions in corporate finance including senior vice president in the Investment Banking Division of Oppenheimer & Co., Inc., New York and co-head of investment banking activities in Central America and the Caribbean for Citicorp Securities, Inc., San José, Costa Rica. Her transactional experience includes initial and follow-on public offerings, merger and acquisition advisory, private placements of both debt and equity, interest rate and currency hedging strategies and strategic analyses. Lisa graduated magna cum laude from Duke University with a B.S. degree in Management Sciences and Finance. Lisa also provides leadership as a board chair and member of two non-profit organizations in San Diego.Lisa Walters

Michael Wise, Partner in the Los Angeles Office, Chair of China Intellectual Property Practice, Perkins Coie LLP

Michael Wise is a Partner in the Los Angeles Office of Perkins Coie LLP and Chair of their China Intellectual Property Practice. Michael’s practice includes patent litigation, patent interferences, patent prosecution, due diligence, portfolio management and strategy advice. Michael represents a variety of clients in the life sciences industry from academic institutions to big pharma clients.

Michael leads the firm’s expansion into the China market counseling companies on patent matters related to China. Michael has also advised the Chinese government agencies and officials on both intellectual property matters generally and matters specific to the life sciences industry between China and the US, including the China National Center for Biotechnology Development under Ministry of Sciences, the State Intellectual Property Office, the Jiangsu Bureau of Fair Trade Department of Trade & Economic Cooperation, Dalian municipal government, Chengdu municipal government, Suzhou Biobay Life Sciences Park, and the Shanghai Zhangjiang Hi-Tech Park.

Michael Wise

Troy Wilson, CEO, Intellikine

Dr. Wilson is President, Chief Executive Officer and a co-founder of Intellikine, an emerging biopharmaceutical company focused on developing selective inhibitors of the PI3K/mTOR pathway. He was formerly co-founder and Chief Business Officer at Ambrx, a biotechnology company focused on the optimization of therapeutic proteins using non-natural amino acids, and he is a co-founder of Phenomix Corporation and Wildcat Discovery. Earlier in his career, Dr. Wilson served as Vice President, Business Development and General Counsel at the Genomics Institute of the Novartis Research Foundation in San Diego. Dr. Wilson obtained his Ph.D. in bioorganic chemistry from the University of California, Berkeley and his J.D. from New York University.

Troy Wilson

Marietta Wu

Marietta Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. Prior to joining Burrill, Dr. Wu held professional positions with Edwards Lifesciences and Eli Lilly & Company. She was Director of Strategy at Edwards, responsible for the strategic planning in the biologics program. At Eli Lilly & Company Oncology and Integrated Biology, Dr. Wu oversaw finance, business development, pipeline valuation, organizational restructure, and outsourcing strategy. She also worked at Eli Lilly’s M&A Group and with Oncology Discovery Research. Dr. Wu founded BioHorizon, a consultancy focused on value creation in the life sciences industry across the Pacific Rim. She advised a number of biotech startups and venture capital firms. Dr. Wu also has leadership positions in several professional organizations promoting transpacific business initiatives, including serving as secretary-general for the BayHelix Group.

Dr. Wu’s scientific expertise centers on basic and clinical research in oncology and neuroscience. She was selected by Nobel Laureate Dr. Marshall Nirenberg as an IRTA Fellow at the National Institutes of Health. Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences with a focus in biochemistry and molecular biology from Medical College of Ohio, and an MBA from the University of Michigan Business School.

Marietta Wu

Stan Yakatan, Chairman and Co-Founder, Katan Associates

After 35 years as a successful CEO, entrepreneur, and operational manager, Stan Yakatan has dedicated the last 15 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive is far reaching as he has served in an Executive capacity with: New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch.These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with others.

He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world’s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada).

Stan is currently the Chairman and CEO of Grant Life Sciences, Inc. (OTCBB:GRTV) a company developing a revolutionary test for the screening of cervical cancer and as a board member for Biophan Technologies, Inc. (OTCBB:BIPH). Stan serves as the strategic advisor to the state government of Victoria, Australia. Stan is the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool. Stan currently sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity and Phenomenome Discoveries, Inc., a novel biomarker company.

Stan Yakatan

Barbara Yanni,Vice President and Chief Licensing Officer of Merck & Co., Inc.

Barbara Yanni is Vice President and Chief Licensing Officer of Merck & Co., Inc. She leads the Corporate Licensing group which is responsible for negotiating agreements to acquire compounds, programs and new technologies to complement Merck’s research programs and pipeline. Barbara works closely with her scientific and marketing colleagues at Merck to ensure that the company has access to discoveries that will enhance Merck’s ability to bring medicines to patients. Barbara and her team have played a major role in shaping a licensing strategy focused on building strong relationships with partners and potential partners. Merck’s rapid, straightforward and clear dealmaking process has made the company an industry leader in the licensing arena. The result has been a significant increase in Merck’s external relationships in recent years. In the past five years, Merck has executed approximately 250 significant licensing transactions in all stages, from technologies and early research collaborations to Phase III development candidates.

Before joining Corporate Licensing, Barbara was Executive Director of Corporate Development at Merck where she negotiated acquisitions, divestitures and other business arrangements. Barbara has also worked in other positions in Merck’s Finance area including Financial Evaluation and Analysis, Treasury and Tax. She joined Merck in 1985 as Domestic Tax Counsel after working as a tax lawyer for several years at Bristol-Myers and in private practice. Barbara graduated with an A.B. from Wellesley College and a J.D. from Stanford Law School. She also holds a Masters of Law in Taxation from New York University.

Barbara Yanni

Mang Yu, Ph.D., Chief Executive Officer

A winner of “Entrepreneur of 2008” award, Mang started his scientist-entrepreneur career 25 years ago, conducting biomedical research and teaching medical students as a faculty member at Fudan University in Shanghai. Under his direction, his present company, NexBio, has received numerous significant awards from the US government for drug development including a $50M National Institutes of Health contract for the development of Fludase®, NexBio’s novel influenza medicine. In addition, NexBio has received a “Scientific American 50” award for this innovative drug. Prior to founding NexBio, Mang was co-founder and Executive Vice President of Perlan Therapeutics. Perlan’s lead product, ColdSol, a common cold medicine, won the CONNECT Award for Most Innovative New Product in 2002. Prior to Perlan, Mang was a scientific co-founder of Immusol (now ItherX Pharmaceuticals) where he served as Director of Target Discovery and Gene Therapy, working on HIV, HBV, and HCV. Mang has served as a member of the Board of Directors for Bridgetech Holding International, a publicly traded multi-national healthcare company. Mang has published his scientific work extensively and holds numerous patents on anti-viral products. In addition to working with the US government, he is experienced in Venture Capital financing and corporate partnership deals. He holds a Ph.D. degree in Biochemistry & Molecular Biology from Indiana University School of Medicine, and completed his post-doctoral training at UCSD.

Mang Yu

Dr. Dan Zhang

Dr. Dan Zhang has more than 10 year of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO with primary operation in China. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest Italy-based pharmaceutical firms with employees of 2300. Dr. Zhang managed the firm’s entire clinical development program in North American market, including oncology, cardiovascular, CNS, and metabolic development projects, in addition to his global role of drug safety handling.

Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.

Micah Zimmerman, Practice Leader, Asia, Scisive Consulting LP

Micah Zimmerman has 14 years of experience in China pharmaceutical portfolio strategy, in/out licensing opportunities, and healthcare investment strategy in Asia. Micah has managed acquisitions, in-licensing, and joint venture agreements in China and East Asia for investors and marketers in the pharmaceutical and healthcare technology industries. Micah has successfully conducted due diligence on numerous domestic Chinese companies, as well as businesses in Australia, S. Korea, Malaysia, and Singapore. Micah has served as a consultant for private equity investors in Hong Kong and as President Asia Pacific for Hearst Business Media’s FirstDatabank division. Based in Beijing for seven years, Micah founded a leading pharmaceutical market research and management consulting firm in China. Prior to his work in Asia, Micah was based in New York as a biotechnology and pharmaceutical industry consultant for The Wilkerson Group. Micah holds a BA and MA in Economics from Tufts University.

Micah Zimmerman

James Zhu, Ph.D. | Beijing Managing Partner

James is a partner in the firm’s IP group and is one of the key members in the firm for establishing the Shanghai Office. James is also the chief representative for the Beijing office. James’ practice focuses on patent procurement, patent opinion, patent due diligence, intellectual property infrastructure, patent litigation, technology licensing, primarily in the fields of life sciences, medical device, chemical industry and material sciences

James is a frequent author and speaker for various IP related subjects. James has been actively involved with the Biotechnology Industry Organization (BIO) where he has served as a delegation committee member since 2004 and introduced/promoted the presence of the Chinese delegation and pavilion in the BIO annual meetings.James Zhu

Wei-Wei Zhang, MD, PhD, President and Chief Executive Officer

Dr. Zhang is the founder and President of eBioCenter Corporation. Dr. Zhang has 25 years of biomedical research experience, 16 years of continuous efforts and track-records in biotechnology industry business development and corporate operations management, including technology innovation, product development, clinical trials and regulatory affairs, manufacturing, marketing and sales, business development, corporate partnering, fund-raising and listing companies in stock markets.

During last year Dr. Zhang led the eBioCenter Team established the e-platform and multi-facet system that provide e-marketing and e-commerce services in biopharma and life science fields. Prior to eBioCenter, during eight years, Dr. Zhang has led the successful operations of GenWay Biotech, Inc, which resulted in development of the platform for providing protein and antibody solution services and a portfolio of product lines. Dr. Zhang also led GenWay’s marketing team to establish various channels to customers and attained multi-million dollars revenues. In addition, Dr. Zhang also led the Company formed two major OEM supply contracts and several key international partnerships.

Dr. Zhang obtained his M.D. degree in 1982 and M.S. of Toxicology in 1985 from Zhejiang University in China. He came to the United States 1986 in pursuit of PhD in molecular biology. After acquired his PhD degree in 1989, Dr. Zhang fulfilled his postdoctoral and junior faculty training in gene manipulation and transfer at Baylor College of Medicine. From 1989 to 2007, Dr. Zhang has 16 patents either issued or pending. He has published more than 60 peer-reviewed articles and has been invited to write major review articles and to deliver presentations in numerous national and international gene therapy conferences.

Wei-Wei Zhang